Amelia Carro Hevia/LinkedIn
Feb 18, 2026, 15:55
Amelia Carro Hevia: Defining the Future of Cardiovascular Medicine at ACC 2026
Amelia Carro Hevia, Consultant Cardiologist and Researcher at Corvilud Institut, posted on LinkedIn:
”Shaping American College Of Cardiology Meeting
ACC.26 (New Orleans, March 28–30, 2026) has announced a broad late‑breaking program spanning lipid management, hypertension, diabetes, obesity, heart failure (including amyloidosis), arrhythmias, structural heart disease, and AI‑enabled prevention.
What to expect?
Cardiovascular Prevention
Key late‑breaking science at ACC.26 will focus on more intensive lipid and blood‑pressure lowering, as well as dietary and novel lipid‑modifying approaches.
- VESALIUS‑CV – Evolocumab in patients without significant atherosclerosis
- Intensive LDL‑C targeting in established ASCVD: Tests more aggressive LDL‑C thresholds in patients with atherosclerotic cardiovascular disease, with primary endpoints centred on composite cardiovascular events and safety of very low LDL‑C.
- ESSENCE‑TIMI 73b Olezarsen coronary CTA substudy
- CORALreef Lipids / CORALreef HeFH – Enlicitide durability
- RESPECT2 – Coronary CT for lipid management in asymptomatic individuals
- GoFreshRx (DASH‑patterned groceries): Randomized trial where provision of DASH‑aligned groceries to treated hypertensives aims to further lower office and ambulatory blood pressure; primary outcome is reduction in systolic blood pressure over follow‑up.
- Kardinal: A Phase 2 Study of Tonlamarsen For the Treatment of Uncontrolled Hypertension
- Effects of a Food-is-medicine Intervention on Blood Pressure Among Black and Hispanic Adults With Hypertension in Healthy Food Priority Areas: The Thrive Pilot Trial
- AHA25 is simultaneously underscoring disruptive lipid and metabolic strategies, such as first‑in‑human CRISPR‑Cas9 therapy (CTX310) targeting ANGPTL3 for lifelong LDL‑C/triglyceride reduction and Lp(a)‑focused sessions, showing very high professional interest in “one‑shot” and RNA‑based lipid therapies.
Heart Failure/Cardiokidneymetabolic Disease
- Targeted assessment in high‑risk diabetes for undiagnosed HF: A pragmatic strategy trial in high‑risk diabetes populations that systematically screens for unrecognized heart failure (e.g., natriuretic peptides, imaging), with primary outcomes such as HF detection rate and impact on downstream management.
- Long‑term survival and disease stabilization with acoramidis in ATTR‑CM
- Cardiorenal‑metabolic (CKM) framing: Background literature and ESC‑style updates emphasize the CKM spectrum (obesity, diabetes, CKD, HF) and advocate integrated therapy with SGLT2 inhibitors, GLP‑1 RAs and renin–angiotensin–neprilysin modulation, which will likely inform ACC.26 guideline and education sessions.
- ACCEL Lite: SURPASS-CVOT: Effect of Tirzepatide Versus Dulaglutide on MACE
Inflammation, Residual Risk, Ai, And Imaging
- NLRP3 inhibitor VTX3232 ± semaglutide in obesity
- AI retinal‑image trial for ASCVD risk
- CRP‑based residual risk and CKM
- ETHYL-ICOSAPENT: subgroup analysis (lpa), guidelines update
Share your thoughts on this meeting.”
Stay updated with Hemostasis Today.
-
Oct 6, 2026, 04:07Moussa Zein Aldine: Acute Coronary Syndrome Every Minute Matters
-
Oct 6, 2026, 03:13Patrick Taylor: Glow Stack Trend What the Evidence Really Shows
-
Oct 6, 2026, 02:59Preventing Hospital Associated Venous Thromboembolism – Thrombosis Canada
-
Oct 6, 2026, 02:42Treatment of Iron Deficiency With and Without Anemia – American Society of Hematology
-
Oct 6, 2026, 02:36Mouna Sassi: When Clinical and Laboratory Perspectives Meet in Thrombosis Care
-
Oct 6, 2026, 02:35Lucia Stefanini: Platelet Dysfunction and Oxidized Phospholipids in MASLD
-
Oct 6, 2026, 02:18Pablo Corral: Association of Lp(a) With Coronary Atherosclerosis and CV Events
-
Oct 5, 2026, 22:55Steve Humphreys: A Big Thank You to BSHT for Providing Me With a Recent Skills Exchange Award
-
Oct 5, 2026, 22:52William McKeown: Great to Be in Istanbul for the Opening of the EHC 2026